BAYN.DE
$40.21
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
Intraday
Recent News
Health Care Roundup: Market Talk
Find insight on Bayer, Amplifon’s acquisition of GN Store Nord’s hearing-aid business, and more in the latest Market Talks covering the Health Care sector.
Bayer eyes label expansion on Phase III non-diabetic CKD win
If Kerendia secures a label expansion, it would become available to more than half of the overall CKD patient population who have a non-diabetic form of the disease.
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.
What’s at stake for Bayer in its Supreme Court showdown?
A key case being heard by the Supreme Court could help the large pharma put its Roundup litigation to rest.
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab
Cytokinetics (NASDAQ:CYTK) executives told investors at the Barclays healthcare conference that the company’s U.S. launch of MYQORZO is still in its earliest phase but showing what management described as encouraging initial signs, while a key phase 3 readout in non-obstructive hypertrophic cardiomy